secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2021-11-03T23:59:59+00:00
Accession:  0001628280-21-021481
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q3 revenue $96.1M (+11% YoY); narrows 2021 guide to $365-375M
---------------------------------------------------------------------

- GAAP diluted EPS $0.24 vs $0.17 YoY; non-GAAP diluted EPS $0.30 vs $0.24.
- Cash and investments $495.2M, up from $471.6M at June 30; repurchased 1.2M shares in Q3.
- Plans Phase 3 trial in recurrent platinum-resistant ovarian cancer in Q1 2022; updated OS data expected Q1 2022.
- Phase 2 NASH data to be presented at AASLD Nov 12-15; Phase 1b dose-finding trial initiated.
- Relacorilant NDA submission for Cushing's syndrome expected Q2 2023; GRACE and GRADIENT trials enrolling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828021021481/0001628280-21-021481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828021021481/cort-20211103.htm
  HTML page:      https://secwatch.observer/filing/0001628280-21-021481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer